Cellectis Partners with Sanofi for Anti-CD52 Antibody Alemtuzumab Over ALLO-647; Could Sanofi Apply Alemtuzumab Learnings to Kiadis’s Pipeline?
On Tuesday, May 11, Cellectis announced (press release) a partnership and supply agreement with Sanofi for alemtuzumab (anti-CD52 monoclonal antibody) as a lymphodepletion agent for allogeneic CAR-Ts. Below, Celltelligence provides insights on how Sanofi may leverage Cellectis’s collaboration to increase their presence within the cell therapy space while discussing Cellectis’s choice of alemtuzumab over Allogene’s ALLO-647 as a lymphodepleting agent in their clinical programs.